Real-World data reveals Luspatercept's impact on MDS patients

NCT ID NCT06851065

Completed Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked back at medical records of 418 patients with lower-risk myelodysplastic syndromes (MDS) who had not previously used erythropoiesis-stimulating agents (ESAs). Researchers examined how luspatercept was used in everyday practice, including dosing, treatment changes, and outcomes like blood transfusion needs and disease progression. The goal was to understand the real-world effectiveness of luspatercept in this patient group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Luspatercept
What this could lead to: If results are positive, this could help doctors understand how well luspatercept works in everyday practice for MDS patients.
What could go wrong: This is a retrospective chart review, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

RTI Health Solutions

Raleigh, North Carolina, 27709-2194, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.